Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

FUROSEMIDE

All injection strengths: Limited Use (codes 481, 657)

Furosemide Injection USP · DIN 02527502 · 10mg/mL · injection solution (Preservative Free)

Limited Use — Reason for Use code 481, 657 requiredDormant since 2026-08-03 · checked 2026-09-02 · What does dormant mean?
StatusLimited Use — Reason for Use code 481, 657 required
Write on scriptLU code 481, 657 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 481, 657
Reason for Use code 481 For the management of patients receiving palliative care*. Coverage limit: LU Authorization Period: 1 year Coverage limit: *The patient must have a progressive life-limiting illness and require this medication for palliative purposes. Reason for Use code 657 For the treatment of patients receiving care at home* who have failed or are unable to tolerate oral alternatives, and who require an injectable option to manage their condition. Coverage limit: LU Authorization Period: 1 year Coverage limit: *e.g., home care recipients, long-term care home residents.
No interchangeable product listed in the Ontario extract
Furosemide Injection USP · DIN 02527502 Manufacturer: Jamp Pharma Corporation; listing date 2024-03-28 Health Canada: Dormant since 2026-08-03 · brand FUROSEMIDE INJECTION USP · ATC C03CA01 FUROSEMIDE · form Solution · route Intravenous, Intramuscular · ingredients FUROSEMIDE 10 MG/ML · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Furosemide Injection USP: Formulary list price $0.6055/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6055 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101656 · Verify on the e-Formulary ↗ (DIN 02527502)

Source record
DIN 02527502: Furosemide Injection USP Raw flags: sec12=Y, sec3=Y Item: 402800047; group id 558; item number 1496; lccId 00272; manufacturer id JPC Source form: Inj Sol (Preservative Free); strength: 10mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.6055; ministry $0.6055 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02527502 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101656
Interchangeable products
Furosemide Injection USP · DIN 00527033 · $0.6055
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02527502
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2026-08-03 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (40:28 Diuretics) and how they are covered

Matched class: 40:28 Diuretics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMILORIDE HCL, METOLAZONE, SPIRONOLACTONE Some products covered without a code (check the product listing): AMILORIDE HCL & HYDROCHLOROTHIAZIDE, CHLORTHALIDONE, HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE & SPIRONOLACTONE, HYDROCHLOROTHIAZIDE & TRIAMTERENE, INDAPAMIDE 40:28 Diuretics

AMILORIDE HCL

· 1 products · General benefit · strengths: 5mg · Tab

AMILORIDE HCL & HYDROCHLOROTHIAZIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 5mg & 50mg · Tab

CHLORTHALIDONE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 50mg · Tab

HYDROCHLOROTHIAZIDE

· 12 products · Off-Formulary Interchangeable, not an ODB benefit (3), Listed, not a benefit (2), General benefit (7) · strengths: 12.5mg, 25mg, 50mg · Tab

HYDROCHLOROTHIAZIDE & SPIRONOLACTONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 25mg & 25mg, 50mg & 50mg · Tab

HYDROCHLOROTHIAZIDE & TRIAMTERENE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 25mg & 50mg · Tab

INDAPAMIDE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 1.25mg, 2.5mg · Tab

METOLAZONE

· 1 products · General benefit · strengths: 2.5mg · Tab

SPIRONOLACTONE

· 8 products · General benefit · strengths: 25mg, 100mg · Tab

MIDODRINE HCL

· 10 products · Listed, not a benefit (2), Limited Use, codes 01 (8) · strengths: 2.5mg, 5mg · Tab

TOLVAPTAN

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 15mg & 15mg, 30mg & 15mg, 45mg & 15mg, 60mg & 30mg, 90mg & 30mg · 14-Tabs Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 40:28
Full class listing Related classes: 40:12 Replacement Agents, 40:18 Potassium-Removing Resins, 40:40 Uricosuric Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TEVA-FUROSEMIDE (furosemide) is indicated for:  The treatment of edema associated with congestive heart failure, cirrhosis of the liver and renal disease including, nephrotic syndrome, as well as other edematous states amenable to diuretic therapy.  Can also be used alone in the control of mild to moderate hypertension, or in combination with other antihypertensive agents in more severe cases. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controllable with furosemide alone. 3 Pediatrics When administered to children, TEVA-FUROSEMIDE therapy should be instituted in the hospital, in carefully selected patients, under close observation with frequent monitoring of serum electrolytes (see DOSAGE AND ADMINISTRATION section). The available pediatric data does not allow for a recommendation of a specific age range in this population. Geriatrics (> 61 years of age) Use in the geriatric population is associated with differences in safety (see WARNINGS AND PRECAUTIONS). https://pdf.hres.ca/dpd_pm/00055547.PDF PM date: March 24, 2020 Source product: TEVA-FUROSEMIDE; DIN 00337730; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)